Our portfolio of investment opportunities
With thorough due diligence process and careful experimental verification, we effectively de-risk our early investment opportunities, ensuring optimal value for our investors
For investors
Type of Investments
Pre-seed funding:
-
Direct investment in pre-company stage biotech projects
-
Participation in acceleration programs through investments in dedicated and regulated funds or selected projects
Seed funding:
-
Investment in NewCos/start-ups established based on incubated projects or positively concluded due diligence processes
-
Typically ranging from €1.5 to €4 million, often supplemented with non-dilutive grant financing
Series A funding of Start-ups:
-
Investment in pre-clinical development stage companies following pre-seed and/or seed financing
Current Opportunities
-
Selected projects from Danube Labs and the DanubeNeuro dedicated fund
-
2 NewCos to be incorporated from the DanubeLabs acceleration program
-
Portfolio includes Eveliqure Biotechnologies, Calyxha Biotechnologies, Algonist Biotechnologies
Get in touch
We're here to collaborate and innovate -
contact us to start the conversation
For Partnering
We actively seek partners for the next phase of commercialization of our drug development projects, through co-development or licensing.
Therapeutic fields
-
Cardiovascular and metabolic diseases
-
Lung fibrosis
-
Cancer immunotherapy
-
Anti-infectives
Therapeutic modalities
-
Small molecules
-
RNA therapeutics
-
Biologics (antibodies, proteins, peptides)